This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Glaxosmithkline Biologicals Sa. Active years: 2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012
Title: Martine Boyer: Innovator in Cancer Immunotherapy
Introduction
Martine Boyer is a prominent inventor based in Laval, Canada. She has made significant contributions to the field of cancer immunotherapy through her innovative research and development of fusion proteins. Her work aims to enhance the immune response against cancer cells, providing new avenues for treatment.
Latest Patents
Martine Boyer holds a patent for a fusion protein that comprises an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1. This invention may also include carriers, fusion partners, or similar components. The methods for preparing, formulating, and utilizing these fusion proteins are also detailed in her patent. These proteins are particularly useful as vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells. She has 1 patent to her name.
Career Highlights
Martine Boyer is associated with GlaxoSmithKline Biologicals SA, where she continues to work on groundbreaking research in the field of immunotherapy. Her dedication to advancing cancer treatment has positioned her as a key figure in her field.
Collaborations
Some of her notable coworkers include Normand Blais and Vincent Brichard, who collaborate with her on various projects aimed at improving cancer therapies.
Conclusion
Martine Boyer's innovative work in developing fusion proteins represents a significant advancement in cancer immunotherapy. Her contributions are paving the way for new treatment options that could benefit many patients in the future.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile